Phil Nadeau
Stock Analyst at TD Cowen
(2.87)
# 1,166
Out of 4,667 analysts
22
Total ratings
50%
Success rate
43.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRS Syros Pharmaceuticals | Downgrades: Hold | n/a | $0.28 | - | 1 | Nov 13, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $55 → $65 | $58.68 | +10.78% | 2 | Nov 6, 2024 | |
| BIIB Biogen | Maintains: Buy | $300 → $275 | $157.41 | +74.71% | 6 | Oct 31, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $125 → $120 | $62.28 | +92.68% | 1 | Aug 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $500 | $447.50 | +11.73% | 7 | Jul 23, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Outperform | n/a | $25.58 | - | 1 | Mar 3, 2023 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | n/a | $49.49 | - | 1 | Jul 7, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | n/a | $8.90 | - | 1 | Nov 23, 2021 | |
| ANNX Annexon | Initiates: Outperform | n/a | $5.34 | - | 1 | Aug 18, 2020 | |
| KZR Kezar Life Sciences | Initiates: Outperform | n/a | $7.50 | - | 1 | Jul 16, 2018 |
Syros Pharmaceuticals
Nov 13, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.28
Upside: -
Rhythm Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $55 → $65
Current: $58.68
Upside: +10.78%
Biogen
Oct 31, 2024
Maintains: Buy
Price Target: $300 → $275
Current: $157.41
Upside: +74.71%
BioMarin Pharmaceutical
Aug 6, 2024
Maintains: Buy
Price Target: $125 → $120
Current: $62.28
Upside: +92.68%
Vertex Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $450 → $500
Current: $447.50
Upside: +11.73%
Enliven Therapeutics
Mar 3, 2023
Initiates: Outperform
Price Target: n/a
Current: $25.58
Upside: -
MoonLake Immunotherapeutics
Jul 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $49.49
Upside: -
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.90
Upside: -
Annexon
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.34
Upside: -
Kezar Life Sciences
Jul 16, 2018
Initiates: Outperform
Price Target: n/a
Current: $7.50
Upside: -